Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brickell Biotech and Kaken ink derma deal

This article was originally published in Scrip

Executive Summary

Miami-based Brickell Biotech is licensing its BBI-4000, a novel, topical soft-anticholinergic in development for patients with primary axillary hyperhidrosis, to Japan's Kaken Pharmaceuticals. Kaken will have the rights to develop and commercialize the drug in Japan – the world's second biggest dermatology market – and some other Asian countries. In return, the Japanese firm will pay Brickell an upfront sum and milestone payments based on certain objectives. Tiered royalties based on sales will also be paid to Brickell following launch. No further terms of the agreement have been released. BBI-4000 is an anticholinergic, which works by blocking the action of acetylcholine, a molecule that transmits the signals within the nervous system responsible for a number of functions, including activating the sweat glands. Soft-anticholinergics like BBI-4000 exert their action topically and are metabolized rapidly into a less active metabolite when they reach the blood system. It is thought this could allow effective doses to be used without the limiting systemic side-effects associated with other drugs in this class. Brickell is a clinical-stage company that focuses on developing and commercializing innovative drugs for skin diseases. Kaken is a specialty pharmaceutical company with a strong presence in dermatology and orthopedics. Its main R&D focus is on inflammation, immunology, pain and antifungals.

You may also be interested in...



Will The COVID-19 Pandemic Shake Up Access To Medicines?

Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.

Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.

Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

Topics

UsernamePublicRestriction

Register

SC028319

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel